AU2020370758B2 - Preventative or therapeutic agent for tauopathy - Google Patents

Preventative or therapeutic agent for tauopathy

Info

Publication number
AU2020370758B2
AU2020370758B2 AU2020370758A AU2020370758A AU2020370758B2 AU 2020370758 B2 AU2020370758 B2 AU 2020370758B2 AU 2020370758 A AU2020370758 A AU 2020370758A AU 2020370758 A AU2020370758 A AU 2020370758A AU 2020370758 B2 AU2020370758 B2 AU 2020370758B2
Authority
AU
Australia
Prior art keywords
substituted
tauopathy
tau
inhibitor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020370758A
Other languages
English (en)
Other versions
AU2020370758A1 (en
Inventor
Makoto Higuchi
Keiko IMAMURA
Haruhisa Inoue
Maiko Ono
Naruhiko SAHARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
National Institutes For Quantum Science and Technology
Original Assignee
Kyoto University NUC
National Institutes For Quantum Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC, National Institutes For Quantum Science and Technology filed Critical Kyoto University NUC
Publication of AU2020370758A1 publication Critical patent/AU2020370758A1/en
Application granted granted Critical
Publication of AU2020370758B2 publication Critical patent/AU2020370758B2/en
Assigned to KYOTO UNIVERSITY, National Institutes for Quantum Science and Technology reassignment KYOTO UNIVERSITY Amend patent request/document other than specification (104) Assignors: KYOTO UNIVERSITY, NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020370758A 2019-10-25 2020-10-20 Preventative or therapeutic agent for tauopathy Active AU2020370758B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019194758 2019-10-25
JP2019-194758 2019-10-25
PCT/JP2020/039450 WO2021079887A1 (ja) 2019-10-25 2020-10-20 タウオパチーの予防又は治療剤

Publications (2)

Publication Number Publication Date
AU2020370758A1 AU2020370758A1 (en) 2022-06-02
AU2020370758B2 true AU2020370758B2 (en) 2025-08-14

Family

ID=75620677

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020370758A Active AU2020370758B2 (en) 2019-10-25 2020-10-20 Preventative or therapeutic agent for tauopathy

Country Status (7)

Country Link
US (1) US20220296548A1 (https=)
EP (1) EP4049679A4 (https=)
JP (1) JP7649999B2 (https=)
CN (1) CN114599397B (https=)
AU (1) AU2020370758B2 (https=)
CA (1) CA3159067A1 (https=)
WO (1) WO2021079887A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0446570A2 (en) * 1990-01-02 1991-09-18 Warner-Lambert Company Gabapentin and its derivatives for treating neurodegenerative diseases
WO2008004067A2 (en) * 2006-06-30 2008-01-10 Pfizer Products Inc. Alpha-2-delta-1 selective compounds for disorders of the nervous system

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2327285C (en) 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
WO2009029173A1 (en) * 2007-08-23 2009-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptogenesis
EP2657219B1 (en) 2007-09-28 2014-12-10 Daiichi Sankyo Company, Limited Intermediate for producing bicyclic y-amino acid derivative
US20110287014A1 (en) * 2008-11-24 2011-11-24 Arnon Rosenthal Antibodies directed against calcium channel subunit alpha2/delta and methods using same
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
KR20170085792A (ko) * 2016-01-15 2017-07-25 서울대학교산학협력단 Tsp-1을 포함하는 알츠하이머병 예방 또는 치료용 조성물
JP7162302B2 (ja) * 2016-10-07 2022-10-28 国立大学法人京都大学 Ｆｔｌｄの予防又は治療剤及びそのスクリーニング方法
JP2019194758A (ja) 2018-05-01 2019-11-07 キヤノン株式会社 情報処理装置、情報処理方法、およびプログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0446570A2 (en) * 1990-01-02 1991-09-18 Warner-Lambert Company Gabapentin and its derivatives for treating neurodegenerative diseases
WO2008004067A2 (en) * 2006-06-30 2008-01-10 Pfizer Products Inc. Alpha-2-delta-1 selective compounds for disorders of the nervous system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUPASITTHUMRONG, T. ET AL.: "Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 85, no. 4, 2018, pages 690-703 *

Also Published As

Publication number Publication date
WO2021079887A9 (ja) 2022-04-14
EP4049679A1 (en) 2022-08-31
CN114599397B (zh) 2024-05-28
JPWO2021079887A1 (https=) 2021-04-29
JP7649999B2 (ja) 2025-03-24
EP4049679A4 (en) 2023-11-01
US20220296548A1 (en) 2022-09-22
WO2021079887A1 (ja) 2021-04-29
CA3159067A1 (en) 2021-04-29
AU2020370758A1 (en) 2022-06-02
CN114599397A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
Caballero et al. Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice
Usenovic et al. Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells
Guix et al. Tetraspanin 6: a pivotal protein of the multiple vesicular body determining exosome release and lysosomal degradation of amyloid precursor protein fragments
Nygaard Targeting Fyn kinase in Alzheimer’s disease
Morel et al. Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system
Ohnishi et al. Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly
Pujadas et al. Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer’s disease
Prati et al. 3, 4-Dihydro-1, 3, 5-triazin-2 (1 H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease
Robinson et al. Upregulation of PGC‐1α expression by A lzheimer's disease‐associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP
Johnson et al. CSF1R inhibitors induce a sex-specific resilient microglial phenotype and functional rescue in a tauopathy mouse model
Hur et al. Identification of novel γ-secretase-associated proteins in detergent-resistant membranes from brain
JP2002515437A (ja) アミロイド症を調整するためのイオン透過担体を含む組成
Sanchez-Martin et al. Regulation of the autophagic PI3KC3 complex by laforin/malin E3-ubiquitin ligase, two proteins involved in Lafora disease
Delaidelli et al. Translational control in brain pathologies: biological significance and therapeutic opportunities
JP6868568B2 (ja) ホスファターゼ選択的および非選択的なホスファターゼ阻害剤を選択するための方法
Liu et al. An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease
Dumbacher et al. Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer’s disease
Krogsaeter et al. Lysosomal proteomics reveals mechanisms of neuronal apoe4-associated lysosomal dysfunction
AU2020370758B2 (en) Preventative or therapeutic agent for tauopathy
Seddigh et al. cis P-tau accumulation triggers neurodegeneration after ischemic stroke
Lee et al. 4-Acyl-3, 4-dihydropyrrolo [1, 2-a] pyrazine derivative rescued the hippocampal-dependent cognitive decline of 5XFAD transgenic mice by dissociating soluble and insoluble Aβ aggregates
HK40075042A (en) Preventative or therapeutic agent for tauopathy
WO2021074418A1 (en) Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
KR101888785B1 (ko) 퇴행성 뇌질환 치료제 스크리닝 방법 및 이를 위한 키트
Wang et al. Pharmacologic inhibition of PCBP2 biomolecular condensates relieves Alzheimer’s disease

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY

Free format text: FORMER NAME(S): KYOTO UNIVERSITY; NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY

Owner name: KYOTO UNIVERSITY

Free format text: FORMER NAME(S): KYOTO UNIVERSITY; NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY

FGA Letters patent sealed or granted (standard patent)